dc.contributor | Vall d'Hebron Barcelona Hospital Campus |
dc.contributor.author | Liu, Mark C. |
dc.contributor.author | Chipps, Bradley |
dc.contributor.author | Muñoz Gall, Fco. Javier |
dc.contributor.author | Devouassoux, Gilles |
dc.contributor.author | Bergna, Miguel |
dc.contributor.author | Smith, Steven G. |
dc.date.accessioned | 2022-01-13T17:33:32Z |
dc.date.available | 2022-01-13T17:33:32Z |
dc.date.issued | 2021-05-10 |
dc.identifier.citation | Liu MC, Chipps B, Munoz X, Devouassoux G, Bergna M, Smith SG, et al. Benefit of switching to mepolizumab from omalizumab in severe eosinophilic asthma based on patient characteristics. Respir Res. 2021 May 10;22:144. |
dc.identifier.issn | 1465-993X |
dc.identifier.uri | https://hdl.handle.net/11351/6793 |
dc.description | Asma; Tractament de l'asma; Eosinòfils |
dc.description.sponsorship | This post hoc analysis and the parent study (GSK ID: 204471; ClinicalTrials.gov number: NCT02654145) were funded by GSK. |
dc.language.iso | eng |
dc.publisher | BMC |
dc.relation.ispartofseries | Respiratory Research;22 |
dc.rights | Attribution 4.0 International |
dc.rights.uri | http://creativecommons.org/licenses/by/4.0/ |
dc.source | Scientia |
dc.subject | Asma - Tractament |
dc.subject | Eosinofília |
dc.subject | Avaluació de resultats (Assistència sanitària) |
dc.subject.mesh | Pulmonary Eosinophilia |
dc.subject.mesh | /drug therapy |
dc.subject.mesh | Drug Substitution |
dc.subject.mesh | Treatment Outcome |
dc.title | Benefit of switching to mepolizumab from omalizumab in severe eosinophilic asthma based on patient characteristics |
dc.type | info:eu-repo/semantics/article |
dc.identifier.doi | 10.1186/s12931-021-01733-9 |
dc.subject.decs | eosinofilia pulmonar |
dc.subject.decs | /farmacoterapia |
dc.subject.decs | sustitución de medicamentos |
dc.subject.decs | resultado del tratamiento |
dc.relation.publishversion | https://doi.org/10.1186/s12931-021-01733-9 |
dc.type.version | info:eu-repo/semantics/publishedVersion |
dc.audience | Professionals |
dc.contributor.organismes | Institut Català de la Salut |
dc.contributor.authoraffiliation | [Liu MC] Divisions of Allergy and Clinical Immunology, Pulmonary and Critical Care Medicine, Johns Hopkins Asthma and Allergy Center, Baltimore, MD, USA. [Chipps B] Capital Allergy and Respiratory Disease Center, Sacramento, CA, USA. [Munoz X] Servei de Pneumologia, Vall d’Hebron Hospital Universitari, Barcelona, Spain. Ciber Enfermedades Respiratorias, Madrid, Spain. [Devouassoux G] Service de Pneumologie, Hôpital de la Croix Rousse, Hospices Civils de Lyon, UCB Lyon, Lyon, France. [Bergna M] Respiratory Research, CEMER, Vicente Lopez, Buenos Aires, Argentina. [Smith SG] Respiratory Therapeutic Area, GSK, Research Triangle Park, NC, USA |
dc.identifier.pmid | 33971856 |
dc.identifier.wos | 000656440500002 |
dc.rights.accessrights | info:eu-repo/semantics/openAccess |